glp 1 risk of cancer Glucagon-like peptide-1 receptor agonists and gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials GLP-1 receptor agonists confer 'modest'
Description
These take the form of orally-administered pills or injectables that can be taken at a lower frequency, both of which have the potential to bring down costs and increase the appeal for patients who dislike self-injection
December 2023: Judge James Cain, Jr
The market is expected to climb to US$ 211.8 Bn by 2035
Tirzepatide came off the FDA shortage list in December 2024 (enforcement discretion ended March 2025)
The short half-life means drug accumulation from a double dose can cause severe GI side effects
